Agenda

Day 1 - Wednesday, 26 June

8:00 – 8:45
Registration open & coffee

GENERAL SESSION

FUTURE THERAPEUTIC APPROACHES: PRECISION MEDICINE, REGENERATIVE MEDICINE AND NEW MODALITIES

08:45 - 09:00
Opening
1

Opening
Marek Tyl, Health Horizons

9:00 – 9:20
Keynote
1 Turning science into medicine: Power of precision medicine
Dr. Stefan Platz, AstraZeneca
09:20 – 10:00
Moderated discussion
1 On the way towards regenerative medicine: from cell therapy to tissue and organ replacement
Prof. Alicia El-Haj, University of Birmingham
Melanie Matheu, Prellis Biologics, Inc.
Dmitry Kuzmin, 4BIO Capital
Ronald Li,Ming Wai Lau Center for Reparative Medicine, Karolinska Institute, Novoheart
Lorenz Mayr, GE Healthcare Life Sciences
10:20 - 10:45
Fireside chat
1 CRISPR, gene editing and what's beyond
Lisa Melton, Nature Biotechnology
Steve Rees, AstraZeneca
Alasdair Russell, Cancer Research UK
10:45 - 11:05
COFFEE BREAK

SESSION 1

CO-CREATION BETWEEN DISCIPLINES AND STAKEHOLDERS

SESSION 2

TRANSFORMING BRAIN AND CNS HEALTH

11:05 – 11:25
Keynote
1 Open science and open innovation
Hitesh Sanganee, AstraZeneca
2 Future development in neurodegenerative diseases and mood disorder treatments
John Isaac, Johnson & Johnson Innovation
11:25 – 12:05
Moderated discussion
1 Examples of co-creation to innovate and improve healthcare – Cambridge vs the rest of the world
Sabine Jaccaud, AstraZeneca
María Aguirre Rueda, Ministry for Health, Basque
Hermann Hauser, Amadeus Capital
Olivier Nosjean, Servier
Zoe McDougall, Oxford Nanopore
Matti Ahlqvist, AstraZeneca
Tony Kouzarides, Milner Therapeutics Institute
2 Future therapeutic areas in CNS
John Isaac Johnson & Johnson Innovation
Lothar Krinke, Magstim
Laurence Barker, Dementia Discovery Fund
Nathalie Cartier-Lacave, BrainVectis
Charlie Pearmund , Virtual BodyWorks
12:05 – 12:20
Fire side chat
1 Co-creation at the interface of computing and biology
Hermann Hauser, Amadeus Capital
Jeanette Walker, Cambridge Science Park
2 [12:05 - 12:20] The Human Brain Project
Jan G. Bjaalie, University of Oslo
[12:20 - 12:35] Treating persistent pain
Peter McNaughton, King's College London

GENERAL SESSION

PATIENT-CENTRIC INNOVATION

12:20 - 12:35
Fireside chat
1 Can expensive innovation be accessible and save cost?
Steven Altschuler, Spark Therapeutics
Paul Brackley, Cambridge Independent
12:35 - 13:15
Moderated discussion
1 Patient-centric innovation
Vishal Gulati, Draper Esprit
Rick Thompson,Findacure
Anne Blackwood, Health Enterprise East
Beatriz Silva-Lima, Universidade de Lisboa
Paul Wicks, PatientsLikeMe
Tim Haines, Abingworth LLP
Jon Larruskain, Athletic Club Bilbao
13:15 - 13:30
Keynote
1 The future of digital health
Chris Lowe,University of Cambridge
13:30 - 14:30
LUNCH

SESSION 3

DIGITAL DISRUPTORS: AI AND DATA IN HEALTHCARE

SESSION 4

DRUGGING DIFFICULT TARGETS

14:30 - 14:50
Keynote
1 Data in healthcare: from drug discovery to clinical analysis
Kenji Tekada, Microsoft Research
2 Protein misfolding and disease
Tuomas Knowles, University of Cambridge
14:50 - 15:10
Science frontiers keynote
1 Digital health and data in the pharmaceutical industry
Andrew Fried, IBM
2 Systematic ways of targeting difficult drug targets
Malcolm Weir, Sosei-Heptares
15:10 - 15:50
Moderated Discussion
1 Machine learning: from genomics and novel targets to better medicines and diagnoses
Andrew Fried, IBM
Alex Zhavoronkov, Insilico Medicine
Maria Chatzou, Lifebit Biotech
Slavé Petrovski, AstraZeneca
Parminder Ruprah, GTN
2 [15:10 - 16:00]
Drugging disordered targets
Jonathan Hay, Delin Ventures
Tuomas Knowles, University of Cambridge
Sunil Shah, O2H Ventures
Markus Zweckstetter, Max Planck Institute
Chris Torrance, PhoreMost
Sam Cohen,Wren Therapeutics
15:50 - 16:05
Short Keynote
1 Machine learning and advance tissue imaging analysis
Richard Goodwin, AstraZeneca
2 [16:00 - 16:20] Targeted protein degradation in drug discovery
Alessio Ciulli, University of Dundee
16:05 - 16:20
Keynote
1 DigiTwins project
Lesley Ogilvie, DigiTwins
2
16:20 - 16:40
COFFEE BREAK

SESSION 5

INTEGRATIVE MEDICINE: PUTTING THE PATIENT IN THE CENTRE

SESSION 6

NANOMEDICINE AND NANOTECHNOLOGIES

16:40 - 17:00
Keynote
1 Convergence of food and health
Ian Charles, Quadram Institute
2 Nanotechnologies for the health industry
Lars Montelius, Lund University
[17:00 - 17:15] Delivering medicine with nanotechnology
Sir Mark Welland, University of Cambridge
17:00 - 17:40
Moderated Discussion
1 Microbiome and the merging of food and healthcare
Ian Charles, Quadram Institute
Beatriz Silva-Lima, Universidade de Lisboa
Robert Tansley, CIC
Trevor Lawley, Microbiotica
Dirk Hadrich, European Commission
Laura Moore, Nell
Carlos Montes, Food Academy
2 [17:15 - 17:55] Nanomedicines on the horizon
Joy Wolfram, Mayo Clinic
Simó Schwartz, CIBBIM Nanomedicine
Eric Mayes, Endomag
Sanyogitta Puri, AstraZeneca
Sir Mark Welland, University of Cambridge
Susanne Bremer-Hoffmann, European Commission
Dr. Mingxing Wei, Cellvax
17:40 - 17:55
Science frontiers Keynote
1 Leveraging the microbiome for precision diagnosis and treatment
Trevor Lawley, Microbiotica
2
17:55 - 18:10
Fireside Chat
1 What is your scientific narrative – integrating KOLs opinions with customer opinions
Gunjan Bhardwaj, Innoplexus
2 Extracellular vesicles in nanomedicines
Joy Wolfram, Mayo Clinic
Simó Schwartz, CIBBIM Nanomedicine
18:10
COCKTAILS

Day 2 - Thursday, 27 June

08:00
Registration open & coffee

GENERAL SESSION

HOW TO REVOLUTIONISE CLINICAL TRIALS

09:00 - 09:20
Keynote
1 Demonstrating value - the necessary tension between controlled vs uncontrolled clinical trials
Rory O'Connor, Pfizer
09:20 - 10:00
Moderated Discussion
1 Translating controlled data into populational value - how controlled trials can be used to predict the response in normal patient populations
Martin Landray,Health Data Research UK
Joanne M. Hackett,Genomics England
Solange Corriol-Rohou, AstraZeneca
Janet Valentine, Clinical Practice Research Datalink
Tomasz Sablinski, Transparency Life Sciences
Beatriz Silva-Lima, Universidade de Lisboa
Hans Constandt, Ontoforce
10:00 - 10:15
Fireside chat
1 Clinical data security, integrity and quality - learnings from the financial industry
Jason Potts, RMIT University
Ann Taylor, Chief Medical Officer, AstraZeneca
Ana Perales, Barclays UK Ventures

GENERAL SESSION

MANAGING CANCER

10:15 - 11:30
Keynote
1 Cancer as a managable disease
Sir Leszek Borysiewicz, Cancer Research UK
10:30 - 11:10
Moderated Discussison
1 Prevention, early detection and future therapies in oncology
Sir Leszek Borysiewicz, Cancer Research UK
Steve Jackson, Gurdon Institute
John Cassidy, Cambridge Cancer Genomics
Cesare Spadoni, aPODD Foundation
Patrizia Paterlini-Bréchot, Paris Descartes University
Susan Critchlow, Oncology, AstraZeneca
11:10 - 11:25
Fireside Chat
1 Advances in cancer treatment and early diagnosis
Jane Grogan, Genentech
Anna Williamson, Roche Pharma Partnering
11:25 - 11:45
COFFEE BREAK

STARTUP PITCHING

11:45 - 13:30

13:30 - 14:30
LUNCH

SESSION 7

THE COST OF HEALTH - NOVEL APPROACHES TO FUNDING INNOVATION

SESSION 8

VIRTUAL REALITY IN CLINICAL PRACTICE AND CARE PROVISION

14:30 - 14:45
Keynote
1 Funding alliances
Harren Jhoti, Astex Pharmaceuticals
2 [14:30 - 14:35] Introductury talks
14:45 - 15:30
Moderated Discussion
1 Partner to innovate: Evolving landscapes of healthcare innovation, new partnership models and investor profiles
Sonia Benhamida,DNB Bank, Healthcare
Ed Rayner, Arix
Paul-Peter Tak, Kintai Therapeutics Inc.
Pavithra Sundaresan, Johnson & Johnson Innovation
Ian Tomlinson, Apollo Therapeutics
Makoto Ohori, Astellas Pharma Inc.
2 [14:35 - 15:45] Challenges and opportunities of Applied VR in Healthcare
Robert Fine, IVRHA
Fran Ayalasomayajula, HP
Amy Hedrick, Cleanbox Technology
Richard Vincent, FundamentalVR
15:30 - 15:45
Fireside Chat
1 Supporting healthcare innovation with new funding models
Paul-Peter Tak, Kintai Therapeutics Inc.
Robert Tansley - Operating Partner, Cambridge Innovation Capital
COFFEE BREAK

SESSION 9

TOWARDS HEALTHY LONGEVITY

SESSION 10

START-UP SHOWCASE

16:05 -16:25
Keynote
1 Ageing as a new therapy area
Aubrey de Grey, SENS Research Foundation
16:25 - 17:05
Moderated Discussion
1 Live long and prosper: Extending lifespan and healthspan
Daniel Ives, Shift Bioscience Ltd
Alexandra Bause, Apollo Ventures
Jane McDermott, Centre for Ageing Better
Bernardo Lemos, Harvard T.H. Chan School of Public Health
Marc Ramis Castelltort, Senolytic Therapeutics Inc.
Attila Csordas, AgeCurve Limited
17:05 - 17:25
Science frontiers keynote
1 Ribosomal DNA and novel biomarkers of ageing
Bernardo Lemos, Harvard T.H. Chan School of Public Health
17:25 - 17:45
Fireside chat
1 Ageing start-up company challenges
Aubrey de Grey, SENS Research Foundation
Alexandra Bause, Apollo Ventures

STARTUP PITCHING WINNER ANNOUNCEMENT

17:50 - 18:05

18:05
COCKTAIL